HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report released on Monday morning.
“We continue to believe that selinexor could be approved for use in r/ r DLBCL patients, and we are encouraged by the data.”,” HC Wainwright’s analyst wrote.
A number of other research analysts also recently issued reports on the company. BidaskClub downgraded Karyopharm Therapeutics from a buy rating to a hold rating in a research note on Saturday, September 29th. Wedbush upgraded Karyopharm Therapeutics from a neutral rating to an outperform rating and set a $19.00 price objective for the company in a research note on Friday, November 9th. ValuEngine downgraded Karyopharm Therapeutics from a strong-buy rating to a buy rating in a research note on Thursday, October 11th. B. Riley initiated coverage on Karyopharm Therapeutics in a research note on Friday, November 30th. They issued a buy rating and a $23.00 price objective for the company. Finally, Robert W. Baird restated a buy rating and issued a $25.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The company has an average rating of Buy and an average price target of $22.90.
Shares of NASDAQ:KPTI opened at $10.56 on Monday. The firm has a market capitalization of $631.36 million, a price-to-earnings ratio of -3.76 and a beta of 3.91. Karyopharm Therapeutics has a 1 year low of $9.00 and a 1 year high of $21.71.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.09. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.21 million. Karyopharm Therapeutics had a negative return on equity of 104.50% and a negative net margin of 502.90%. On average, equities research analysts expect that Karyopharm Therapeutics will post -3.04 earnings per share for the current fiscal year.
In other news, EVP Christopher Brett Primiano sold 10,000 shares of the stock in a transaction on Monday, September 10th. The stock was sold at an average price of $18.90, for a total transaction of $189,000.00. Following the completion of the transaction, the executive vice president now owns 7,881 shares in the company, valued at approximately $148,950.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Kauffman sold 9,600 shares of the stock in a transaction on Monday, November 26th. The stock was sold at an average price of $11.00, for a total value of $105,600.00. Following the transaction, the chief executive officer now owns 521,743 shares of the company’s stock, valued at approximately $5,739,173. The disclosure for this sale can be found here. Insiders have sold a total of 77,500 shares of company stock valued at $1,191,831 in the last quarter. 13.26% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of KPTI. Virtu Financial LLC bought a new position in shares of Karyopharm Therapeutics during the 3rd quarter worth $195,000. Verition Fund Management LLC bought a new position in Karyopharm Therapeutics in the 3rd quarter worth about $242,000. UBS Group AG boosted its stake in Karyopharm Therapeutics by 761.8% in the 1st quarter. UBS Group AG now owns 19,632 shares of the company’s stock worth $264,000 after purchasing an additional 17,354 shares during the period. Fox Run Management L.L.C. bought a new position in Karyopharm Therapeutics in the 3rd quarter worth about $266,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Karyopharm Therapeutics by 38.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $277,000 after purchasing an additional 4,556 shares during the period. Institutional investors own 71.21% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
See Also: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.